Aprea Therapeutics share price logo

Aprea Therapeutics

NASDAQ: APRE

$0.84

+0.04

(+4.46%)

as on

Aprea Therapeutics Stock Performance

as on September 2, 2026 at 2:15 pm IST

  • Day's Low

    Day's High

    $0.79
    $0.90
    downward going graph

    5.95%

    Downside

    7.14%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $0.55
    $1.69
    downward going graph

    34.76%

    Downside

    101.19%

    Upside

    downward going graph

Aprea Therapeutics share price movements today

Previous Close
$0.80
Open
$0.81
Volume
840.7K
Market Cap
$10.1M
Day's Low - High
$0.79 - $0.90
52 Week Low - High
$0.55 - $1.69

Aprea Therapeutics Historical Returns

1 Month Return
+ 34.79 %
3 Month Return
+ 9.36 %
1 Year Return
-46.77 %
3 Year Return
-77.89 %
5 Year Return
-99.13 %

Aprea Therapeutics Stock Fundamentals & Key Indicators

Check Aprea Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$10.1M

EPS (TTM)

-1.29

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-0.65

Industry PE ratio

-1.4626335877862595

PEG Ratio

-0.010243032231322344

EBITDA

-12.3M

Revenue (TTM)

-

Profit Margin

0.00%

Return On Equity TTM

-46.72%

Aprea Therapeutics Stock Valuation

Track how Aprea Therapeutics P/E has moved over time to understand its valuation trends.

Aprea Therapeutics in the last 5 years

  • Overview

  • Trends

Lowest (-1.67x)

December 31, 2021

Industry (-1.46x)

December 31, 2025

Today (-0.44x)

December 31, 2025

Highest (-0.00x)

December 31, 2022

LowHigh

Today’s Price to Earnings Ratio: -0.44x

Aprea Therapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Aprea Therapeutics with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
BUY$10.1M-99.13%-0.650.00%NA
BUY$44.6B614.61%NA0.00%NA
BUY$137.9B174.9%31.9286.04%NA
BUY$61.6B-61.21%-7.98-12.57%NA
BUY$82.3B21.91%19.984.86%0.44%

Stock Returns calculator for Aprea Therapeutics Stock including INR - Dollar returns

The Aprea Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

Aprea Therapeutics investment value today

Current value as on today

₹57,736

Returns

-₹42,264

(-42.26%)

Returns from Aprea Therapeutics Stock

-₹46,497 (-46.5%)

Dollar Impact

₹4,233 (+4.23%)

Analyst Recommendation on Aprea Therapeutics Stock

Based on 3 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 3 analysts, 100% of analysts recommend a 'BUY' rating for Aprea Therapeutics. Average target price of $3.55

Aprea Therapeutics Share Price Target

Get share price movements and forecasts by analysts on Aprea Therapeutics.

What analysts predicted

76.34%UPSIDE

Target Price

$3.55

Current Price

$0.84

Analyzed by

3 Analysts

Target

$3.55

Aprea Therapeutics target price $3.55, a slight upside of 76.34% compared to current price of $0.84. According to 3 analysts rating.

Indian Investors' Interest in Aprea Therapeutics Stock

Search interest for Aprea Therapeutics Stock has increased by 705% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:705% versus previous 30 day period

Aprea Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
0
0
0
0
0
0
-
-
-
-
Gross Profit
-1
-1
-2
-2
-2
-1
-
-
0
-
Operating Income
-3
-3
-4
-3
-4
-3
-3
-2
-3
-4
EBITDA
-2
-3
-3
-2
-3
-3
-2
-2
-3
-3
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-2
-3
-3
-2
-3
-3
-2
-2
-3
-3
Income Tax Expense
-
-
-
-
-
-
-
-
-
-
Net Income
-2
-3
-3
-2
-3
-3
-2
-2
-3
-3
Net Profit Margin
-320.52%
-355.45%
-702.66%
-1046.21%
-1428.39%
-1519.00%
0.00%
0.00%
0.00%
0.00%

Aprea Therapeutics Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
-
-
-
-
-
-
0
1
-
Gross Profit
-
-
0
0
0
-16
0
-7
-
Operating Income
-15
-16
-29
-52
-37
-113
-15
-14
-13
EBITDA
-15
-15
-27
-53
-36
-37
-14
-12
-12
Interest Expense
0
0
0
0
-
0
-
-
-
Depreciation
-
-
0
0
0
0
0
0
0
Income Before Tax
-15
-15
-28
-53
-37
-112
-14
-12
-12
Income Tax Expense
-
-
-
-
-
-
-
-
-
Net Income
-15
-15
-28
-53
-36
-112
-14
-12
-12
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
98.79%
-523.16%
0.00%

Aprea Therapeutics Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-2
-3
-3
-2
-3
-3
-2
-2
-3
-3
Operating Cash Flow
-3
-3
-2
-3
-3
-3
-3
-2
-2
-3
Investing Cash Flow
0
0
-
-
-
-
-
-
-
0
Financing Cash Flow
14
0
0
0
0
0
0
3
34
-1
Change in Cash
10
-3
-2
-3
-3
-2
-2
0
31
-5

Aprea Therapeutics Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-15
-15
-28
-53
-37
-112
-14
-12
-12
Operating Cash Flow
-14
-15
-26
-41
-37
-25
-12
-13
-12
Investing Cash Flow
-
0
0
0
-
-
0
0
-
Financing Cash Flow
23
56
92
0
1
0
5
14
4
Change in Cash
10
41
64
-41
-35
-24
-7
1
-8

Mutual Funds that own Aprea Therapeutics Stock

Check out the Mutual Funds with significant holdings in Aprea Therapeutics.

Funds
Holdings
Shares Held
Fidelity Concord Street Trust
0.685188%
86273
VANGUARD INDEX FUNDS
0.155839%
19622

Global Institutional Holdings in Aprea Therapeutics

Funds
Holdings
Vanguard
0.2%

Aprea Therapeutics News & Key Events

  • img

    Today's Timeline - 28 August

    Fri, 07:07 PM

    -

    Aprea Therapeutics expands global IP portfolio, enhancing protection for precision oncology programs and extending exclusivity for key candidates.

Insights on Aprea Therapeutics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 537.7% return, outperforming this stock by 584.5%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Revolution Medicines, Inc. Common Stock has given 37.1% return, outperforming this stock by 115.0%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 7 days, APRE stock has moved down by -14.7%

About Aprea Therapeutics

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.
OrganisationAprea Therapeutics
Headquarters3805 Old Easton Road, Doylestown, PA, United States, 18902
IndustryBiotechnology
CEODr. Oren Gilad Ph.D.
E-voting on sharesClick here to vote

Key Management of Aprea Therapeutics

Name

Title

Dr. Oren Gilad Ph.D.

Co-Founder, CEO, President & Director

Mr. John P. Hamill CPA

Senior VP, CFO, Principal Accounting Officer & Secretary

Dr. Lars B. Abrahmsen Ph.D.

Senior VP & Chief Scientific Officer

Mr. Brian Wiley

Senior Vice President of Corporate Development & Strategy

Dr. Michel Afargan Ph.D.

Head of Pharmacology Development

Mr. Ze'ev Weiss B.Sc., C.P.A.

Chief Business Advisor

Dr. Eugene P. Kennedy F.A.C.S., M.D.

Chief Medical Advisor

Ms. Andrea Epstein

Controller

FAQs

What is Aprea Therapeutics share price today?

Aprea Therapeutics share price today is $0.84 as on at the close of the market. Aprea Therapeutics share today touched a day high of $0.90 and a low of $0.79.

What is the 52 week high and 52 week low for Aprea Therapeutics share?

Aprea Therapeutics share touched a 52 week high of $1.69 on and a 52 week low of $0.55 on . Aprea Therapeutics stock price today i.e. is closed at $0.84,which is 50.30% down from its 52 week high and 53.28% up from its 52 week low.

What is Aprea Therapeutics's market capitalisation today?

Aprea Therapeutics market capitalisation is $0.00T as on .

How to invest in Aprea Therapeutics Stock (APRE) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Aprea Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Aprea Therapeutics Shares that will get you 1.7857 shares as per Aprea Therapeutics share price of $0.84 per share as on September 2, 2026 at 8:45 am IST.

What is the minimum amount required to buy Aprea Therapeutics Stock (APRE) from India?

Indian investors can start investing in Aprea Therapeutics (APRE) shares with as little as ₹94.96 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹949.60 in Aprea Therapeutics stock (as per the Rupee-Dollar exchange rate as on ). Based on Aprea Therapeutics share’s latest price of $0.84 as on September 2, 2026 at 8:45 am IST, you will get 11.9048 shares of Aprea Therapeutics. Learn more about fractional shares .

What are the returns that Aprea Therapeutics has given to Indian investors in the last 5 years?

Aprea Therapeutics stock has given -99.13% share price returns and 30.36% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?